SOURCE: Medical News Today
DATE: April 29. 2008
EXCERPT: "Chronically irregular heartbeat (atrial fibrillation) affected women who had taken Merck's bisphosphonate drug Fosamax (alendronate) to combat the bone-thinning disease osteoporosis nearly twice as often as women who had never used it according to new research from the US." more
RELATED PUBMED LINK:
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008 Apr 28;168(8):826-31.